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Abstract: CD4þCD28 T cells also called CD28 null cells have been
reported as increased in the clinical setting of acute coronary syndrome.
Only 2 studies previously analyzed peripheral frequency of CD28 null
cells in subjects with acute ischemic stroke but, to our knowledge,
peripheral frequency of CD28 null cells in each TOAST subtype of
ischemic stroke has never been evaluated. We hypothesized that CD4þ
cells and, in particular, the CD28 null cell subset could show a different
degree of peripheral percentage in subjects with acute ischemic stroke in
relation to clinical subtype and severity of ischemic stroke.
The aim of our study was to analyze peripheral frequency of CD28
null cells in subjects with acute ischemic stroke in relation to TOAST
diagnostic subtype, and to evaluate their relationship with scores of
clinical severity of acute ischemic stroke, and their predictive role in the
diagnosis of acute ischemic stroke and diagnostic subtype
We enrolled 98 consecutive subjects admitted to our recruitment
wards with a diagnosis of ischemic stroke. As controls we enrolled 66
hospitalized patients without a diagnosis of acute ischemic stroke.
Peripheral frequency of CD4þ and CD28 null cells has been evaluated
with a FACS Calibur flow cytometer.
Subjects with acute ischemic stroke had a significantly higher
peripheral frequency of CD4þ cells and CD28 null cells compared
to control subjects without acute ischemic stroke. Subjects with cardi-
oembolic stroke had a significantly higher peripheral frequency of
CD4þ cells and CD28 null cells compared to subjects with other
TOAST subtypes. We observed a significant relationship betweenD, Valentina Arna Maida, MD,
sario Squadrito, MD, and Antonio Pinto, MD
These findings seem suggest a possible role for a T-cell component
also in acute ischemic stroke clinical setting showing a different
peripheral frequency of CD28 null cells in relation of each TOAST
subtype of stroke.
(Medicine 94(20):e813)
Abbreviations: ACS = acute coronary syndrome, AMI = acute
myocardial infarction, ANOVA = analysis of variance, AOUP =
Azienda Ospedaliera Universitaria Policlinico, BBB = blood brain
barrier, Bcl-2 = B-cell lymphoma, brain CT = brain computed
tomography, CD4þCD28cells = cluster differentiation (CD), CEI
= cardioembolic infarct, ECG = electrocardiogram, EDTA =
ethylenediaminetetraacetic acid, IFN-g = interferon gamma, IgG1-
FITC = IgG1 antibodies conjugated with fluorescein isothiocyanate,
IgG2a-PE = IgG2a conjugated with phycoerythrine, IL-1b =
interleukin 1b, IL-2R (IL-2Ra) = interleukin 2 receptor (IL2RA),,
IL-6 = interleukin 6, LAAS = large artery atherosclerosis, LAAS =
large artery atherosclerotic stroke, LAC = LACunar infarct, md-
rankin = modified rankin, MRI = magnetic resonance imaging,
NIHSS = National Institutes of Health Stroke Scale, ODE = other
determined etiology, PBMCs = peripheral blood mononuclear cells,
ROC = receiver operating characteristic, SD = standard deviation,
TIA = transient ischemic attack, TNF-a = tumor necrosis alfa,
TOAST = trial Org 10172 in acute stroke treatment, Treg CD4þ
CD25 null cells = T-regulator CD4þ CD25 null cells, UDE =
undetermined etiology.
INTRODUCTION
I n the late 1980s, Hansen and Martin described a subset of TCD4þcells with defective CD28 antigen called CD4þ
CD28 cells also called CD28 null.1–3 This subset of T cells
shows several characteristics of pathogenic cells and they are
less susceptible to regulation by Treg CD4þ CD25 null cells4,5
and produce high amounts of g-interferon and tumor necrosis
alfa (TNF-a) hence becoming proinflammatory cells. Some
studies reported that these types of cells have increased in the
clinical setting of acute coronary syndrome (ACS).4–6
Previous findings by Liuzzo et al4,7,8 in subjects with ACS
could suggest a relationship between T-cell activation and
ischemic neuronal damage since a possible epidemiologic,
pathogenic, and clinical parallel between ACS and acute
cerebrovascular events such as acute ischemic stroke, plausibly
suggesting a possible role for T CD4þ CD28 cells also inathogenesis.
viously analyzed peripheral frequency of
bjects with acute ischemic stroke. The
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former conducted by Nadareishvili et al9 prospectively eval-
uated subjects with acute ischemic stroke analyzing the relation-
ship between CD28 null cells and recurrence of a
cerebrovascular event showing that high peripheral levels of
CD28 null cells were significantly associated with event recur-
rence risk at 1-year follow-up. In a second study by Nowik
et al,10 authors reported that CD4þ CD28 null cells were
involved in mechanisms that increase stroke risk.
Thus, we hypothesized that CD4þ cells and, in particular,
the CD4þ CD28 subset could show a different degree of
increased peripheral percentage in subjects with acute ischemic
Tuttolomondo et alstroke
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The aim of this study was as follows:(1) to analyze peripheral frequency of CD4þCD28 cells in
subjects with acute ischemic stroke in relation to TOAST
diagnostic subtype;(2) to evaluate relationship of peripheral frequency of
CD4þCD28 cells with scores of clinical severity of
acute ischemic stroke,(3) to evaluate the ability of peripheral frequency of
CD4þCD28 cells to predict stroke and its subtypes
classified according TOAST classification.
MATERIALS AND METHODS
We enrolled consecutive subjects admitted to our recruit-
ment wards (ward of Internal Medicine, AOUP ‘‘P.Giaccone’’
Palermo; ward of Vascular Medicine AOUP ‘‘P.Giaccone’’,
Pronto Soccorso Unit, Fondazione Istituto S. Raffaele/Giglio
of Cefalu`) with a diagnosis of acute ischemic stroke, in a
recruitment period from June 2011 to December 2013. As
controls we enrolled hospitalized patients without a diagnosis
of acute ischemic stroke, admitted in the same period to our
Internal Medicine Ward for any cause other than acute cardi-
ovascular and cerebrovascular events. All enrolled patients
underwent a general and neurological evaluation and an instru-
mental evaluation (ECG, ECG-holter 24 hours, epicranial vessel
echography, brain CT or MRI, transthoracic echocardiography,
and, in some cases, transesophageal).
Ischemic stroke has been defined as ‘‘a clinical syndrome
of rapidly developing symptoms or signs of focal loss of
cerebral function with symptoms lasting more than 24 hours
and no apparent cause other than the vascular origin.’’11 Patients
and controls were excluded if they had 1 of the exclusion
criteria: rheumatologic disorders, chronic inflammatory dis-
ease, acute systemic infections, recent venous thrombosis,
recent acute myocardial infarction (AMI) (within 3 months),
and recent cerebrovascular event (TIA or stroke within
6 months) (all these conditions may influence inflammatory
cytokine and cell levels).
CRITERIA FOR EVALUATION OF
CARDIOVASCULAR RISK FACTORS FOR CASES
AND CONTROLS
Type 2 diabetes mellitus was determined using a clinically
based algorithm that considered age at onset, presenting weight
and symptoms, family history, onset of insulin treatment, and
history of ketoacidosis. Hypertension was defined according to
the 2007 European Society of Hypertension and the Europeanety of Cardiology Guidelines (2007 ESH/ESC 2007) as
ws: (i) systolic blood pressure (SBP) >140mmHg, and/or
olic blood pressure (DBP) >90mmHg in patients not
www.md-journal.comreceiving antihypertensive medication; (ii) previously docu-
mented diagnosis of hypertension in patients with the concur-
rent use of diet or antihypertensive medication regardless of
current SBP and DBP values. Hypercholesterolemia was
defined as total serum cholesterol 200mg/dL and hyper-
triglyceridemia as total serum triglyceride 150mg/dL on
the basis of the National Cholesterol Education Program–
Adult Treatment Panel III reports that define this cutoff for
optimal total serum cholesterol and triglyceride levels. All
patients had blood pressure, serum glucose, creatinine, serum
uric acid, serum cholesterol levels, serum triglyceride levels,
and urinary albumin excretion values measured on admission to
the hospital. Coronary artery disease was identified on the
basis of a history of physician-diagnosed angina, myocardial
infarction, or any previous revascularization procedure
determined by a questionnaire. Cerebrovascular disease
(TIA/ischemic stroke) was identified by patient history,
specific neurologic examination performed by specialists,
and hospital or radiological records (brain computed tomogra-
phy or brain magnetic resonance) of definite TIA or stroke. The
protocol study was approved by Ethics Committee of the
Policlinico P Giaccone Hospital and of Fondazione Istituto
S. Raffaele/Giglio of Cefalu` and all the patients gave their
written informed consent to participate in the study, as well as
for sampling and banking of the biological material. Study
protocol conforms to the ethical guidelines of the 1975 Declara-
tion of Helsinki.
BLOOD SAMPLE COLLECTION TIMING
Blood samples has been drawn after 48 hours after symp-
tom onset owing to the fact that several reports from exper-
imental models to humans12,13 can sustain a possible
‘‘peripheral blood translation’’ of a neuroinflammatory cas-
cade, either in terms of inflammatory cytokines or in terms of
‘‘cellular trafficking,’’ so it is plausible to hypothesize a
peripheral increase of some cell subset of the T-cell population
within 48 hours after an acute ischemic cerebral event. Acti-
vated T-cells on the periphery of the immune compartment once
recruitment by means of cytokines has been fulfilled, enter the
cerebral level through blood brain barrier (BBB) disruption and
thus it appears plausible to expect a higher frequency of some
T-cell subsets on peripheral blood14,15 in parallel with their
course of intracerebral inflow
Cell Isolation, Staining, and Flow Cytometry
Peripheral blood has been drawn at 48 hours after symp-
tom onset and after informed consent had been obtained from
the patient or his/her authorized representative. Peripheral
blood mononuclear cells (PBMCs) have been obtained by
density gradient centrifugation using the lymphocyte separ-
ation medium (ICN Pharmaceutical, Costa Mesa, CA). This
protocol yields an average PBMC composition of 60% T cells,
15% monocytes/macrophages, 10% B cells, and 15% natural
killer cells.16 White cells were obtained from 2mL of periph-
eral EDTA-anticoagulated venous blood. Cells were labeled
with human monoclonal anti-CD4 antibodies conjugated with
fluorescein isothiocyanate and anti-CD28 antibodies conju-
gated with phycoerythrine (Becton, Dickinson and Company 1
Becton Drive Franklin Lakes, New Jersey). Mouse IgG1
antibodies conjugated with fluorescein isothiocyanate
Medicine  Volume 94, Number 20, May 2015(IgG1-FITC) and IgG2a conjugated with phycoerythrine
IgG2a-PE) (Becton Dickinson) were used as the isotype con-
trols. The samples were incubated for 30minutes in the dark at
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
ambient temperature, washed with 5% saline and centrifuged.
The pellet was suspended in 1% formalin. Expression of the
CD28 receptor on lymphocytes was studied with a FACSCa-
libur flow cytometer (FACSCalibur/Sysmex XT1800i dual
platform) operating with CellQuest OS2 software. The popu-
lation of CD4þ CD28 was expressed as a percentage of
CD4þ cells (CD4þ CD28 and CD4þ CD28þ).
STROKE SUBTYPE EVALUATION
The type of acute ischemic stroke was classified according
to the TOAST classification17: large artery atherosclerosis
(LAAS); cardioembolic infarct (CEI); LACunar infarct
(LAC); stroke of other determined etiology (ODE); and stroke
of undetermined etiology (UDE).
FUNCTIONAL EVALUATION
National Institute of Health Stroke Scale (NIHSS) and
Medicine  Volume 94, Number 20, May 2015Scandinavian Stroke Scale (SSS) were used to evaluate acute
neurological deficit grade at 48 hours after admission in all
enrolled patients with acute ischemic stroke.18,19 Modified
TABLE 1. General, Clinical, and Laboratory Variables of Patients
Variables Patients With
Age, y (meanSD) 7
Diabetes (n/%)
Ihypertension (%)
Hypercholesterolemia (n/%)
Atrial fibrillation (n/%)
Previous stroke (n/%)
Previous TIA (n/%)
SAP, mm Hg (mean SD) 1
DAP, mm Hg (meanSD) 8
Glucose blood levels, mmol/L (meanSD) 1
Total cholesterol levels, mmol/L (meanSD) 4
LDL cholesterol levels, mmol/L (meanSD) 2
HDL cholesterol levels, mmol/L (meanSD) 1
Triglycerides, mmol/L (meanSD) 1
WBC, 109/L 9
Neutrophil (%) 6
TOAST subtype
LAAS 38
Lacunar 25
CEI 32
ODE 3
NIHSS (meanSD) 1
SSS (meanSD) 3
mRS (meanSD)
ESR, mm/h 2
CRP, mg/dL
CD4þ cells (%)
CD4þ CD28 (%)
TNF-a, pg/mL 2
IL-1b, pg/mL
IL-6, pg/mL
CD4þ CD28 cells¼ cluster of differentiation 4 positive and cluster of d
positive cells, CRP¼C-reactive protein, DAP¼ diastolic blood pressure,
IL-1b¼ Interleukin-1b, IL-6¼ Interleukin -6, LDL¼ low-density lipoprotei
Health Stroke Scale, SAP¼ systolic blood pressure, SSS¼Scandinavian Str
ORG 10172 in Acute Stroke Treatment, WBC¼white blood count.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Rankin score (mRankin) was used to assess disability grade
at discharge.20
Statistical Analysis
Statistical analysis of quantitative and qualitative data,
including descriptive statistics, was performed for all items.
Continuous data are expressed as mean  standard deviation,
unless otherwise specified. Baseline differences between
groups were assessed by the x2 test or Fisher exact test as
needed for categorical variables, and by the independent Stu-
dent t test for continuous parameters. The univariate analysis of
variance (ANOVA) was performed for parametric variables,
and post hoc analysis with the Bonferroni test was used to
determine whether there were pairwise differences. Linear
regression analysis examined the correlation between various
patient characteristics (independent variables), and CD4þ cells
or CD4þ CD28 cells peripheral percentages (dependent
variable) in simple and multiple regression models; at multi-
CD4þ CD28 Cells in Acute Ischemic Strokevariate analysis we analyzed relationship between prognostic
indexes (SSS, NIHSS, and rankin scores and death) and CD4þ
and CD28 null cell peripheral percentage after adjustment for
With Acute Ischemic Stroke (n: 98) and Controls (n: 67)
Ischemic Stroke (n: 98) Controls (n: 67) P
4.3 12.1 73.7 10.7 0.702
39 (40.2) 30 (44.7) 0.506
85 (87.0) 53 (79.1) 0.203
33 (34.0) 27 (27.8) 0.397
43 (44.3) 28 (28.9) 0.854
47 (48.5) 12 (17.9) 0.0001
12 (12.4) 4 (5.9) 0.207
50.7 28.6 132.1 11.0 0.0001
0.8 14.5 78.9 6.6 0.310
4.6 0.81 6.04 1.92 0.0001
.36 1.13 4.12 0.57 0.110
.45 0.65 2.47 0.64 0.820
.14 0.40 1.01 0.28 0.450
.65 0.58 1.39 0.24 0.310
.35 4.96 7.21 2.14 0.001
7.2 13.1 51.8 9.1 0.005
(39.2) 38.8
(25.8) 25.5
(32. 9) 32.6
(30.9) 3.1
8.4 15.1
0.5 13.8
3.4 1.7
6.6 16.7 14.8 9.1 0.0001
5.4 1.7 3.6 1.8 0.011
51.4 6.8 34.4 6.4 0.0001
5.7 2.4 2.8 0.9 0.0001
8.2 29.3 12.3 4.5 0.0001
7.9 2.6 4.7 1.6 0.0001
8.2 2.4 4.2 1.5 0.0001
ifferentiation 28 negative cells, CD4þ cells¼ cluster of differentiation 4
ESR¼Erytrocyte sedimentation rate, HDL¼ high density lipoprotein,
n, mRS¼modified Rankin Scale score, NIHSS¼National Institutes of
oke Scale score, TNF-a¼ tumor necrosis factor alfa, TOAST¼Trial of
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other variable resulted significant at univariate analysis. To
assess the predictive rate of different cutoff values of CD4 or
CD4CD28 peripheral percentages with regard of stroke and
TOAST subtype, a receiver operating characteristic (ROC)
curve with calculations of area under the curve and 95% CIs
was constructed and sensitivity and specificity values were
calculated. Data were analyzed by the Epi Info software (ver-
sion 6.0, Centers for Disease Control and Prevention, Atlanta,
GA) and IBM SPSS Software 21.0 version (SPSS, Inc., Chi-
cago, IL). All P values were 2-sided and P values <0.05 were
considered statistically significant.
RESULTS
We enrolled 98 subjects with acute ischemic stroke and 66
control subjects. Demographic, laboratory, and clinical vari-
ables of subjects with acute ischemic stroke and control subjects
are reported in Table 1.
Subjects with acute ischemic stroke had a significantly
higher peripheral frequency of CD4þ cells compared to controls
without acute ischemic stroke (51.4 6.8% vs 34.4 6.4%;
Tuttolomondo et alP¼ 0.0001); similarly, ischemic stroke subjects had a signifi-
cantly higher peripheral frequency of CD4þCD28 cells com-
pared to controls without acute ischemic stroke (5.7 2.4% vs
TABLE 2. General, Clinical, and Laboratory Variables of Patients
Variables LAAS (n: 38)
Age, y (meanSD) 72.3 11.9
F/M (n/%) 14/24 (36.8/63.1)
Diabetes (n/%) 16 (42.1)
Ihypertension (%) (n/%) 32 (84.2)
Hypercholesterolemia (n/%) 18 (47.4)
Atrial fibrillation (n/%) 8 (21.1)
Previous stroke (n/%) 18 (47.4)
Previous TIA (n/%) 6 (15.8)
SAP, mm Hg (meanSD) 148.9 31.5
DAP, mm Hg (meanSD) 80.9 13.8
Glucose blood levels, mmol/L (meanSD) 8.66 2.46
Total cholesterol levels, mmol/L (meanSD) 4.37 1.09
LDL cholesterol levels, mmol/L (meanSD) 2.63 0.82
HDL cholesterol levels, mmol/L (meanSD) 1.15 0.33
Triglycerides, mmol/L (meanSD) 1.31 0.64
WBC, 109/L 10.25 4.14
Neutrophil (%) 67.9 12.9
SSSS (meanSD) 31.6 13.0
NIHSS (meanSD) 14.9 12.1
mRS (meanSD) 3.6 1.8
ESR, mm/h 23.8 15.7
CRP, mg/dL 3.471 1.98
CD4þ cells (%) 45.3 6.9
CD4þ CD28 (%) 5.4 1.8
TNF-a, pg/mL 32.2 15.3
IL-1b, pg/mL 7.7 2.0
IL-6, pg/mL 8.4 1.7
CD4þ CD28 cells¼ cluster of differentiation 4 positive and cluster of di
positive cells, CRP¼C-reactive protein, DAP¼ diastolic blood pressure,
IL-1b¼ interleukin-1b, IL-6¼ interleukin-6, LDL¼ low-density lipoprotein
Health Stroke Scale, SAP¼ systolic blood pressure, SSS¼Scandinavian Stro
count.
4 | www.md-journal.com2.8 0.9%; P¼ 0.0001). Stroke subjects also showed higher
cytokine plasma levels such as TNF-a (28.2 29.3 vs 12.3
4.5 pg/mL; P¼ 0.0001), IL-1b (7.9 2.6 vs 4.7 1.6 pg/mL;
P¼ 0.0001) and IL-6 (8.2 2.4 vs 4.2 1.5 pg/mL;
P¼ 0.0001) compared to controls (see Table 1).
Demographic, clinical and laboratory variables of subjects
with acute ischemic stroke in relation to TOAST subtype are
listed in Table 2.
Subjects with cardioembolic stroke showed a significantly
higher peripheral frequency of CD4þ cells compared to sub-
jects with LAAS and lacunar subtype (51.7 6.1% vs
45.3 6.9% vs 43.6 7.5%; P¼ 0.012) and of CD28 null cells
compared to subjects with LAAS and lacunar subtypes
(7.5 2.0% vs 5.4 1.8% vs 3.7 1.5%; P¼ 0.0001). Subjects
with cardioembolic subtype had significantly higher blood
levels of TNF-a (39.6 6.2 vs 32.2 15.3 vs 18.1 10.7 pg/
mL); IL-6 (9.03 1.90 vs 8.44 1.73 vs 7.04 pg/mL;
P¼ 0.006) and IL-1b (7.7 2.0 vs 6.1 2.3 vs 9.3 2.4 pg/
mL) compared to subjects with LAAS and lacunar subtypes (see
Table 2).
Regarding the relationship between immune-inflammatory
Medicine  Volume 94, Number 20, May 2015variables and severity markers (see Table 3), we have observed
no significant relationship between peripheral frequency of
CD4þ cells and chosen stroke severity indicators, whereas
With Acute Ischemic Stroke in Relation of TOAST Subtype
TOAST Subtype
Lacunar (n: 25) Cardioembolic (n: 32) P
73.1 13.7 77.4 11.0 0.302
14/11 (56.5/44) 22/10 (68.7/31.2) 0.058
11 (45.8) 12 (37.5) 0.477
22 (88) 28 (87.5) 0.754
5 (20.8) 9 (28.1) 0.119
7 (28) 27 (84.4) 0.0001
11 (44) 17 (53.1) 0.888
2 (8) 4 (12.5) 0.755
157.0 29.6 149.3 24.9 0.528
83.1 14.1 78.9 16.3 0.769
7.65 2.72 7.70 3.08 0.605
4.29 1.11 4.31 1.21 0.571
2.40 0.87 2.73 1.08 0.850
1.23 0.49 39.7 0.32 0.240
1.45 0.62 1.20 0.42 0.476
9.47 3.34 8.35 6.71 0.340
70.4 10.9 63.7 13.3 0.273
40.5 7.3 21.6 13.1 0.0001
10.0 10.2 29.9 15.3 0.0001
2.1 1.3 4.1 1.1 0.0001
29.6 14.1 27.9 20.8 0.505
3.9 1.7 3.4 2.6 0.987
43.6 7.5 51.7 6.1 0.012
3.7 1.5 7.5 2.0 0.0001
18.0 10.7 39.6 6.2 0.025
6.1 2.3 9.3 2.4 0.0001
7.0 3.2 9.0 1.9 0.006
fferentiation 28 negative cells, CD4þ cells¼ cluster of differentiation 4
ESR¼ erytrocyte sedimentation rate, HDL¼ high-density lipoprotein,
, mRS¼modified Rankin Scale score, NIHSS¼National Institutes of
ke Scale score, TNF-a¼ tumor necrosis factor alfa, WBC¼white blood
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 3. Multivariate Analysis of Relationship Between
Immunoinflammatory and Prognostic Variables
B b B 95% CI Sig (P)
Relationship between CD4þ cells and prognostic variables
SSS 0.068 0.137 0.108–0.244 0.443
NIHSS 0.115 0.790 0.043–0.272 0.151
RS 0.611 0.183 1.514–0.293 0.183
Death 0.997 0.062 0.043–0.272 0.563
Relationship between CD4þ CD28 cells and prognostic variables
SSS 0.049 0.026 0.100–0.001 0.046
NIHSS 0.460 0.023 0.0001–0.091 0.042

RS 0.880 0.131 0.172–0.348 0.501
Death 0.173 0.494 0.809–1.155 0.727
Relationship between TNF-a and prognostic variables
SSS 0.413 0.190 1.188–0.362 0.039
NIHSS 0.044 0.022 0.737–0.649 0.041
mRS 0.935 0.054 4.913–3.042 0.642
Death 6.385 0.091 21.403–8.632 0.401
Relationship between IL-1-b and prognostic variables
SSS 0.053 0.284 0.117–0.012 0.044
NIHSS 0008 0.047 0.049–0.066 0.042
mRS 0.087 0.058 0.417–0.244 0.605
Death 1.093 0.181 2.342–0.156 0.086
Relationship between IL-6 and prognostic variables
SSS 0.008 0.045 0.055–0.071 0.029
NIHSS 0.016 0.097 0.040–0.072 0.032
mRS 0.005 0.003 0.326–0.317 0.978
Death 0.916 0.161 2.129–0.297 0.137
CD4þ CD28 cells¼ cluster of differentiation 4 positive and cluster
of differentiation 28 negative cells, CD4þ cells¼ cluster of differen-
tiation 4 positive cells, IL-1b¼ interleukin-1b, IL-6¼ interleukin-6,
mRS ¼ modified Rankin Scale score, NIHSS¼National Institutes of
Medicine  Volume 94, Number 20, May 2015we observed a significant relationship between peripheral
frequency of CD4þCD28 cells and SSS (b¼0.049;
P¼ 0.046) and NIHSS (b¼0.460; P¼ 0.042) scores.
At multivariate analysis, we reported a significant relation-
ship between TNF-a (P¼ 0.039 and P¼ 0.041), IL-1b (P ¼
0.044 and P¼ 0.042), IL-6 plasma levels (P¼ 0.029 and
P¼ 0.032), SSS and NIHSS scores, whereas CD28 null cell
Health Stroke Scale, SSS¼Scandinavian Stroke Scale score, TNF-
a¼ tumor necrosis factor-a.
After adjustment for atrial fibrillation prevalence.peripheral frequency was significantly associated with inflam-
matory cytokine blood levels at multivariate analysis, such as
IL-6, IL-1b, and TNF-a (see Tables 4 and 5).
TABLE 4. Multivariate Analysis of Relationship Between
CD4þ CD28 Cells and Immunoinflammatory Variables
B b B 95% CI Sig (P)
TNF-a 0.321 0.312 0.120–0.407 0.0001

IL-1b 0.297 0.341 0.160–0.435 0.0001

IL-6 0.261 0.323 0.140–0.397 0.0001

CD4þ CD28 cells¼ cluster of differentiation 4 positive and cluster
of differentiation 28 negative cells, IL-1b¼ interleukin-1b, IL-
6¼ interleukin-6, TNF-a¼ tumor necrosis factor-a.
After adjustment for atrial fibrillation prevalence.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.By means of ROC curve analysis we showed a good
sensitivity and specificity of CD4þ peripheral frequency to
predict ischemic stroke (AUC¼ 0.964, P¼ 0.0001; cutoff
value> 41.2%, sensitivity¼ 90.9, specificity¼ 95.5; see
Figure 1); in regard to the peripheral frequency of CD28
cells ROC curve analysis demonstrated good sensitivity and
specificity to predict stroke (AUC¼ 0.880, P¼ 0.0001;
sensitivity¼ 70.4, specificity¼ 98.5, cutoff value> 4.1%,
(see Figure 1).
The sensitivity and specificity of CD4þ cells to predict
TOAST subtype of ischemic stroke at ROC curve analysis did
not show a significant association with LAAS (AUC¼ 0.638,
P¼ 0.06; sensitivity¼ 68.4, specificity¼ 60.0 cutoff 53.1%),
and cardioembolic subtypes (AUC¼ 0.592, P¼ 0.227;
sensitivity¼ 65.6, specificity¼ 60.0, cutoff value 53).
ROC curve analysis showed good sensitivity and speci-
ficity values of CD28 null cell peripheral frequency to predict
cardioembolic (AUC¼ 0.932, P¼ 0.0001; sensitivity¼ 75.0,
specificity¼ 96.0, cutoff value> 6.1%), and LAAS TOAST
subtypes (AUC¼ 0.787, P¼ 0.0001; sensitivity¼ 78.9,
specificity¼ 72.0, cutoff value> 3.9%) (see Figures 2 and 3).
DISCUSSION
This study found a significantly higher peripheral fre-
quency of CD4þ and CD28 cells in subjects with acute
ischemic stroke compared to controls. Consistent with findings
already reported by previous studies in the clinical setting of
ACSs4,7,8 our results seem to suggest a possible role for a T-cell
component also in ischemic stroke setting.
The acute phase of ischemic stroke is characterized by a
high degree of immune-inflammatory activation in terms of
increased plasma levels of cytokines, adhesion molecules, and
selectins,21,22 and our group previously reported this degree of
inflammatory activation as higher in subjects with cardioem-
bolic subtype compared to the other TOAST subtypes of
stroke.12,13,14,15,23–26
Several reports from experimental models to humans16,27
can sustain a possible ‘‘translation’’ of a neuroinflammatory
cascade, either in terms of inflammatory cytokines or in terms of
‘‘cellular trafficking,’’ so it is plausible to hypothesize a
peripheral increase of some cell subset of the T-cell population
within 48 hours after an acute ischemic cerebral event. Acti-
vated T-cells on the periphery of the immune compartment once
recruitment by means of cytokines has been fulfilled, enter the
cerebral level through BBB disruption and thus it appears
plausible to expect a higher frequency of some T-cell subsets
on peripheral blood16,27 in parallel with their course of
intracerebral inflow.
Among these T-cells, CD28 null cells that show several
characteristics of pathogenic cells and they are less susceptible
to regulation by Treg CD4þ CD25 null cells4,5 and produce
high amounts of g-interferon and TNF-a thus may have a direct
pathogenetic role in neuronal ischemic damage.
Our finding concerning a significant relationship between
T-cell subsets and TOAST subtype of stroke showing a higher
peripheral frequency of CD4þ and CD28 cells in subjects
with cardioembolic subtype compared to lacunar subtype
appear original owing to the fact that to our knowledge, no
study has yet addressed this issue.
At multivariate analysis our findings also showed a sig-
CD4þ CD28 Cells in Acute Ischemic Strokenificant relationship between peripheral frequency of CD28 null
cells and some severity markers such as SSS and NIHSS scores.
Two previous studies, the former by Nadareishvili et al9 did not
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TABLE 5. Area Under ROC Curve, Sensitivity, and Specificity of CD4þ and CD28 Cells Cutoff Values Diagnosis of Ischemic
Stroke and TOAST Subtype
Ischemic stroke
Variable Cutoff (%) Area Under ROC Curve Sensitivity (95% CI) Specificity (95% CI) P
CD4þ cells >41.2 0.964 90.8 (83.3–95.7) 95.5 (87.3–99.0) 0.0001
CD28 cells >4.1 0.880 70.4 (60.3–79.2) 98.5 (91.8–99.7) 0.0001
LAAS
CD4R cells >–53.1 0.638 68.4 (51.3–82.5) 60.0 (38.7–78.8) 0.057
CD28S cells >3.9 0.787 78.9 (62.7–90.4) 72.0 (50.6–87.9) 0.0001
Cardioembolic
CD4R cells >–53 0.592 65.6 (46.8–81.4) 60.0 (38.7–78.8) 0.227
CD28S cells >6.1 0.932 75.0 (56.6–88.5) 96.0 (79.6–99.3) 0.0001
f d
ecei
Tuttolomondo et al Medicine  Volume 94, Number 20, May 2015evaluate the relationship between neurological deficit grade and
CD4CD28 null cell count, whereas Nowik et al10 reported that
the severity of neurological deficits assessed on admission did
not correlate with percentage of CD4þCD28 lymphocytes. It
explains how our observed relationship between CD4þCD28
null cell peripheral percentage and NIHSS and SSS scores
appear a novel finding.
Ischemic stroke induces a profound local inflammatory
response. Within hours, various types of immune cells transmi-
grate over the activated endothelium to invade the damaged
brain in a timed fashion. Although previous studies mostly
focused on neutrophils and monocytes,16,28,29 the role of
lymphocytes, especially T cells in ischemic stroke, has long
been neglected, although T cells are localized in close vicinity
CD4R CD28S cellsU cluster of differentiation 4 positive and cluster o
positive cells, LAASULarge Artery Atherosclerotic Stroke, ROCU r
Treatment.to blood vessels in the infarct boundary as early as 24 hours after
experimental focal cerebral ischemia in rodents.30,31 T cells
have been identified in the brain as early as 24 hours after
FIGURE 1. ROC curves of CD4þ and CD28 cells cutoff values
toward diagnosis of ischemic stroke.
6 | www.md-journal.comischemia.32,33 Involvement of adaptive immunity comes from
studies on the role of lymphocytes in models of focal cerebral
ischemia reporting how ischemia leads to infiltration of the
major lymphocytes subtypes into the ischemic brain.33
Lymphocytes invade the ischemic brain and contribute to
tissue damage, but the rapidity of their deleterious effect is not
consistent with an adaptive immune response targeted to the
brain. Nevertheless, this lymphocyte role in brain ischemia
pathogenesis could offer biological plausibility to our findings
owing to the proinflammatory properties of CD28 null cells4,5
We previously reported that immune-inflammatory acti-
vation of the acute phase of ischemic stroke is associated with
stroke volume and severity degree in terms of acute neurologi-
cal deficit grade evaluated by NIHSS,23 thus the role of CD4þ
ifferentiation 28 negative cells, CD4R cellsU cluster of differentiation 4
ving operator curve, TOASTUTrial of ORG 10172 in Acute StrokeCD28 subset could represent a natural extension of cytokine,
selectins, and adhesion molecule activation. The severity of
neurological symptoms, assumed to reflect the size of the
FIGURE 2. ROC curves of CD4þ and CD28 cells cutoff values
toward diagnosis of cardioembolic subtype of ischemic stroke.
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Medicine  Volume 94, Number 20, May 2015ischemic lesion, correlated with the percentage of CD4þ
CD28 lymphocytes. According to the hypothesis that stroke
is followed by an increase in the number of these cells as a
response to antigens released from injured brain tissue, a higher
percentage of peripheral CD4CD28 null cells could be related to
a more profound brain injury.
The possible neuroinflammatory equivalence between
CD4þ CD28 cell components and cytokine activation just
reported by our group14,23 and other groups21,22 is further con-
firmed by our finding concerning the relationship between fre-
quency of peripheral CD28 null cells and some severity markers
such as the SSS score and the NIHSS, used as indicators of the
degree and type of neurological deficit of the acute phase. The
significant association between levels of CD28 T cells and
serum levels of inflammatory cytokines assessed in our current
study (IL-6, TNF-a, IL-1b) may explain this relationship.
Finally, at ROC curve analysis our findings showed that
CD28 null cell peripheral percentage may be useful to differ-
entiate between stroke subtypes. The greater frequency of
CD4þ CD28 in subjects with ischemic stroke compared to
controls and the significant association with the degree and type
of neurological deficit and with the cardioembolic subtype
offers the possibility to analyze a possible application of the
peripheral levels of the T-cell subset for differentiate stroke and
its diagnostic subtype.
The greater association with the cardioembolic subtype
emphasizes the role of a relationship between increased gravity
and higher extent of cardioembolic stroke lesions23 and the
activation of a subset of T cells such as the CD4þ and CD28
cells compared to the related component of the single plaque
instability, than has been indicated by the few other studies that
have addressed this issue.4–6
Furthermore, good sensibility and specificity for stroke
diagnosis could offer prospects both in the diagnosis of a disease
such as acute ischemic stroke that often enters the differential
FIGURE 3. ROC curves of CD4þ and CD28 cells cutoff values
toward diagnosis of LAAS subtype of ischemic stroke.diagnosis with other acute illnesses, and for which a battery of
diagnostic markers with sufficient sensitivity and specificity is
not available, and for which the assessment of T-cell activation
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.as well as an evaluation of the cytokine activation pathway
could have a possible role in the integration and implementation
of the diagnostic process.
This study has some limitations. First, we do not have any
information about CD28 null peripheral percentage in baseline
conditions prior of stroke occurrence. Second, CD 28 null
peripheral percentage could better represent a proinflammatory
background linked to stroke pathogenesis that a consequence of
brain ischemic event. Third, our stroke patients showed a
significantly higher prevalence of a previous stroke compared
to controls thus, this higher previous cerebrovascular morbidity,
could be linked to the higher degree of CD4þCD28 peripheral
percentage in stroke patients. Fourth, some studies34,35 reported
a finding of lymphopenia after acute ischemic stroke, but
consistent with our findings other studies reported a higher
frequency of some T-cell subsets on peripheral blood14,15 after
an acute ischemic stroke underlyng the role of CD4CD28 null
cells that are only a component of lymphocyte cell family. The
profound damage to the CNS caused by ischemic lesions has
been well documented.
Yet, relatively little is known about the contribution to and
effects on the immune system during stroke. Some authors have
focused on both early and late events in the peripheral immune
system during stroke in mice and have observed an early
activation of splenocytes that conceivably could result in
immune-mediated damage in the developing CNS lesion,37
followed by global immunosuppression that affects the spleen,
thymus, lymph nodes, and circulation that has been reported as
mediated by a stroke-induced apoptosis of CD4þCD28þ cells
in lymphoid organs37,38
Nevertheless, it is conceivable that CD4þ D28 null subset
of T-cells could be resistant to stroke-induced apoptosis. CD4þ
T-cells deficient in CD28 expression and compared with their
CD28þ counterparts, they produce significantly higher levels
of IFN-g giving them the ability to function as proinflammatory
cells. Moreover CD4þ CD28null T cell are highly olygoclonal
and clones persist for years in circulation.36 Longevity of these
cells appears to be related to their relative resistance to spon-
taneous cell death even in the absence of IL-2.39 This phenom-
enon is associated with low levels of expression of the a-chain
of the IL-2R (IL-2Ra), despite their ability to produce large
amounts of IL-2, and an increased expression of the anti-
apoptotic molecule Bcl-2.40–43
In conclusion, we provided evidence of a higher peripheral
percentageof some subsets ofT-lymphocyte cells in subjectswith
acute ischemic stroke, a significant association with neurological
deficit degree, and a predictive role of CD28 null cell peripheral
percentage toward stroke diagnosis and TOAST subtype.
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